How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice
- Author(s)
- Fairley, JL; Nikpour, M; Mack, HG; Brosnan, M; Saracino, AM; Pellegrini, M; Wicks, IP;
- Details
- Publication Year 2023-08-15,Volume 53,Issue #3,Page 311-317
- Journal Title
- Internal Medicine Journal
- Abstract
- Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases including systemic lupus erythematosus (SLE), where it provides beneficial immunomodulation without clinically significant immunosuppression. HCQ can also assist in managing inflammatory arthritis, including rheumatoid arthritis (RA). Debate around toxicity of HCQ in COVID-19 has challenged those who regularly prescribe HCQ to discuss its potential toxicities. Accordingly, we have reviewed the adverse effect profile of HCQ to provide guidance about this therapeutic agent in clinical practice. This article is protected by copyright. All rights reserved.
- Publisher
- Wiley
- Keywords
- Humans; Hydroxychloroquine/adverse effects; Antirheumatic Agents/adverse effects; Friends; covid-19; COVID-19 Drug Treatment; Chloroquine/adverse effects; Lupus Erythematosus, Systemic/drug therapy; adverse effects; cardiotoxicity; hydroxychloroquine; retinopathy; rheumatoid arthritis; safety; systemic lupus erythematosus
- Research Division(s)
- Infectious Diseases And Immune Defence; Inflammation
- PubMed ID
- 35969110/
- Publisher's Version
- https://doi.org/10.1111/imj.15908
- Open Access at Publisher's Site
https://doi.org/10.1111/imj.15908- NHMRC Grants
- NHMRC/1113577,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-08-19 09:30:38
Last Modified: 2023-06-09 09:45:23